Oppenheimer Asset Management Inc. Sells 2,069 Shares of Core Laboratories N.V. (CLB)

Oppenheimer Asset Management Inc. decreased its stake in Core Laboratories N.V. (NYSE:CLB) by 7.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,995 shares of the oil and gas company’s stock after selling 2,069 shares during the period. Oppenheimer Asset Management Inc. owned 0.06% of Core Laboratories worth $2,467,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CLB. Alliancebernstein L.P. lifted its holdings in shares of Core Laboratories by 18.6% in the 1st quarter. Alliancebernstein L.P. now owns 2,494 shares of the oil and gas company’s stock worth $288,000 after purchasing an additional 392 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Core Laboratories by 9.7% in the 2nd quarter. Aperio Group LLC now owns 5,882 shares of the oil and gas company’s stock worth $596,000 after purchasing an additional 518 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Core Laboratories by 6.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 139,549 shares of the oil and gas company’s stock worth $14,133,000 after purchasing an additional 8,774 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Core Laboratories by 54.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 5,562 shares of the oil and gas company’s stock worth $579,000 after purchasing an additional 1,950 shares during the last quarter. Finally, Ridgewood Investments LLC lifted its holdings in shares of Core Laboratories by 26.4% in the 2nd quarter. Ridgewood Investments LLC now owns 3,892 shares of the oil and gas company’s stock worth $394,000 after purchasing an additional 813 shares during the last quarter.

Several analysts recently commented on the company. BidaskClub cut Core Laboratories from a “sell” rating to a “strong sell” rating in a research report on Monday, August 14th. Credit Suisse Group upgraded Core Laboratories from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a research report on Thursday, August 24th. They noted that the move was a valuation call. Cowen restated a “hold” rating and issued a $100.00 target price on shares of Core Laboratories in a research report on Friday, September 1st. ValuEngine cut Core Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $115.00 target price on shares of Core Laboratories in a research report on Friday, September 1st. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $110.40.

Core Laboratories N.V. (CLB) opened at $101.00 on Monday. Core Laboratories N.V. has a 1 year low of $86.55 and a 1 year high of $125.83. The stock has a market capitalization of $4,458.88, a price-to-earnings ratio of 55.19 and a beta of 1.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.81 and a current ratio of 2.18.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.04. Core Laboratories had a return on equity of 52.89% and a net margin of 12.06%. The company had revenue of $166.20 million for the quarter, compared to analysts’ expectations of $160.94 million. During the same period last year, the firm earned $0.38 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. sell-side analysts predict that Core Laboratories N.V. will post 1.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, November 21st. Stockholders of record on Friday, October 20th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.18%. The ex-dividend date of this dividend was Thursday, October 19th. Core Laboratories’s dividend payout ratio (DPR) is presently 126.44%.

TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/11/oppenheimer-asset-management-inc-sells-2069-shares-of-core-laboratories-n-v-clb.html.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

What are top analysts saying about Core Laboratories N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Core Laboratories N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit